ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
NIR-II Fluorescent Protein Created by In Situ Albumin-Tagging for Sensitive and Specific Imaging of Blood-Brain Barrier Disruption.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cyanobacteria-derived near-infrared autofluorescent exosomes enabling synergistic brain lesion imaging and neuroprotection.Bioactive materials · 2026Article
- Organic small-molecule NIR-II fluorophores for tumor phototheranostics.Light, science & applications · 2026Review
- NIR-II Fluorescent Protein Created by In Situ Albumin-Tagging for Sensitive and Specific Imaging of Blood-Brain Barrier Disruption.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Imaging albumin in vivo is a reliable strategy to visualize blood-brain barrier (BBB) disruption by detecting the dye-labeled albumin leaking into brain parenchyma. Although Evans Blue (EB) and indocyanine green (ICG) dyes have been applied to assess BBB impairment, their naked-eye observation or near-infrared-I (NIR-I) imaging window limit the imaging sensitivity and contrast for this promising "albumin-based" strategy. Herein, an albumin-specific tagged near-infrared-II (NIR-II) probe is engineered as a chromophore to construct fluorescent proteins (FPs) in situ for assessing BBB disruption in stroke. The optimized chromophore, C7-1080, can covalently bind to albumin through nucleophilic substitution, forming FPs without adjuvant. Notably, the albumin effectively acts as a brightness enhancer and stability regulator for chromophores through the tight clamping effect. Theoretical simulation, proteomics, and protein mutation techniques are employed to investigate the binding behavior between albumin and chromophore. The in situ NIR-II FPs construction strategy facilitates high-precision dual-channel imaging of BBB disruption and cerebral vessels during ischemic stroke when combined with the IR-808Ac probe. Overall, the in situ albumin-specific tag holds promise for diagnosing and monitoring strokes, presenting a tool for investigating the progression and therapeutic responses of related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.